Abcam (LON:ABC) Given New GBX 1,370 Price Target at Liberum Capital
Abcam (LON:ABC) had its target price hoisted by Liberum Capital from GBX 1,290 ($16.97) to GBX 1,370 ($18.02) in a research note issued to investors on Wednesday morning, Stock Target Advisor reports. Liberum Capital currently has a hold rating on the stock.
A number of other research firms have also issued reports on ABC. Peel Hunt reaffirmed an add rating on shares of Abcam in a report on Wednesday, March 4th. Royal Bank of Canada decreased their price objective on Abcam from GBX 1,300 ($17.10) to GBX 1,250 ($16.44) and set a sector performer rating on the stock in a report on Wednesday, December 18th. Panmure Gordon lowered Abcam to a sell rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. lifted their price objective on Abcam from GBX 1,134 ($14.92) to GBX 1,188 ($15.63) and gave the stock a neutral rating in a report on Tuesday, March 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. Abcam has a consensus rating of Hold and a consensus target price of GBX 1,345.60 ($17.70).
ABC traded down GBX 94 ($1.24) during midday trading on Wednesday, reaching GBX 1,107 ($14.56). The company’s stock had a trading volume of 705,539 shares, compared to its average volume of 497,233. The stock has a market cap of $2.28 billion and a P/E ratio of 50.78. The company has a fifty day simple moving average of GBX 1,234.72 and a 200 day simple moving average of GBX 1,259.84. Abcam has a twelve month low of GBX 1,058 ($13.92) and a twelve month high of GBX 1,523 ($20.03).
In other news, insider Jonathan Simon Milner sold 1,100,000 shares of Abcam stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of GBX 1,412 ($18.57), for a total transaction of £15,532,000 ($20,431,465.40).
Abcam Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
See Also: What are gap-down stocks?
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.